Apellis Pharmaceuticals (NASDAQ:APLS) PT Lowered to $57.00 at Wedbush

Apellis Pharmaceuticals (NASDAQ:APLS) had its price objective decreased by stock analysts at Wedbush from $67.00 to $57.00 in a report issued on Wednesday, Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Wedbush’s price objective suggests a potential upside of 16.14% from the stock’s current price.

APLS has been the subject of several other reports. The Goldman Sachs Group increased their target price on Apellis Pharmaceuticals from $65.00 to $90.00 and gave the company a “buy” rating in a research report on Tuesday, January 9th. UBS Group increased their target price on Apellis Pharmaceuticals from $87.00 to $89.00 and gave the company a “buy” rating in a research report on Monday, March 4th. Oppenheimer increased their target price on Apellis Pharmaceuticals from $75.00 to $79.00 and gave the company an “outperform” rating in a research report on Tuesday, January 30th. Raymond James increased their target price on Apellis Pharmaceuticals from $67.00 to $106.00 and gave the company a “strong-buy” rating in a research report on Thursday, January 11th. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $81.00 target price on shares of Apellis Pharmaceuticals in a research report on Tuesday, February 6th. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $77.93.

Apellis Pharmaceuticals Trading Down 5.3 %

NASDAQ APLS traded down $2.74 on Wednesday, hitting $49.08. 917,101 shares of the company were exchanged, compared to its average volume of 1,487,443. The company’s 50 day moving average price is $61.22 and its 200-day moving average price is $57.00. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.10 and a quick ratio of 2.50. The firm has a market capitalization of $5.92 billion, a P/E ratio of -10.99 and a beta of 0.88. Apellis Pharmaceuticals has a twelve month low of $19.83 and a twelve month high of $94.75.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its earnings results on Tuesday, February 27th. The company reported ($0.73) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.73). The business had revenue of $146.38 million for the quarter, compared to analyst estimates of $143.34 million. Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. The firm’s revenue was up 545.9% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.50) EPS. Analysts predict that Apellis Pharmaceuticals will post -1.33 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Pascal Deschatelets sold 69,107 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $54.17, for a total transaction of $3,743,526.19. Following the completion of the sale, the insider now owns 1,115,983 shares of the company’s stock, valued at $60,452,799.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Apellis Pharmaceuticals news, insider Mark Jeffrey Delong sold 9,913 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $56.90, for a total value of $564,049.70. Following the completion of the sale, the insider now owns 54,693 shares of the company’s stock, valued at $3,112,031.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Pascal Deschatelets sold 69,107 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $54.17, for a total value of $3,743,526.19. Following the completion of the sale, the insider now directly owns 1,115,983 shares of the company’s stock, valued at approximately $60,452,799.11. The disclosure for this sale can be found here. Insiders sold 406,651 shares of company stock valued at $25,130,257 over the last 90 days. Company insiders own 7.50% of the company’s stock.

Institutional Investors Weigh In On Apellis Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. Cim Investment Management Inc. lifted its holdings in shares of Apellis Pharmaceuticals by 3.6% in the first quarter. Cim Investment Management Inc. now owns 4,744 shares of the company’s stock valued at $313,000 after purchasing an additional 163 shares in the last quarter. Sippican Capital Advisors grew its position in Apellis Pharmaceuticals by 1.1% during the fourth quarter. Sippican Capital Advisors now owns 16,004 shares of the company’s stock worth $958,000 after buying an additional 170 shares in the last quarter. Advisor Group Holdings Inc. lifted its stake in shares of Apellis Pharmaceuticals by 6.9% in the 4th quarter. Advisor Group Holdings Inc. now owns 3,249 shares of the company’s stock valued at $167,000 after acquiring an additional 209 shares during the last quarter. Treasurer of the State of North Carolina lifted its stake in shares of Apellis Pharmaceuticals by 0.5% in the 3rd quarter. Treasurer of the State of North Carolina now owns 43,800 shares of the company’s stock valued at $1,666,000 after acquiring an additional 230 shares during the last quarter. Finally, First Horizon Advisors Inc. lifted its stake in shares of Apellis Pharmaceuticals by 69.0% in the 3rd quarter. First Horizon Advisors Inc. now owns 649 shares of the company’s stock valued at $25,000 after acquiring an additional 265 shares during the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).